ReviewMolecular neurobiology2026
Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative cognitive dysfunction (POCD) is a frequent neurological complication in older surgical patients, leading to substantial declines in quality of life and placing a considerable burden on society. This review provides a comprehensive overview of how mitochondrial dysfunction contributes to POCD, including disrupted energy metabolism, excessive reactive oxygen species production, calcium imbalance, and abnormalities in mitochondrial dynamics and quality control processes. These mitochondrial impairments further trigger neuroinflammation and activate multiple cell death pathways. In addition, the review examines current mitochondria-targeted therapeutic strategies and their underlying mechanisms, highlighting the neuroprotective roles of agents such as SS-31, Mdivi-1, P110, and NLRP3 inhibitors in preclinical studies. It also explores the promise of multi-target combinational treatments, time-specific interventions, and individualized therapeutic approaches. Finally, the review discusses key barriers to clinical translation such as limited blood-brain barrier permeability, unintended drug effects, and altered pharmacokinetics in the elderly and considers emerging technologies, including nanocarrier drug-delivery systems and AI-guided personalized treatment plans, as potential tools for achieving more precise prevention and management of POCD.
Indexed as
Identifiers
42570043What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.